Prednisolone Acetate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Prednisolone Acetate
- Prednisolone Acetate: From Topical Ocular Corticosteroid to Serous Conjunctivitis (Non-viral)
Prednisolone Acetate: From Topical Ocular Corticosteroid to Serous Conjunctivitis (Non-viral)
One-Sentence Summary
Prednisolone acetate is a corticosteroid registered in South Africa as eye drops (Pred-mild 5 ml). The TxGNN model predicts it may be effective for serous conjunctivitis except viral, but there are currently 0 clinical trials and 0 publications for this specific indication, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the SAHPRA registration record (registered as eye drops) |
| Predicted New Indication | Serous conjunctivitis except viral |
| TxGNN Prediction Score | 99.74% (model rank 1772) |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for this drug. Prednisolone acetate is a topical corticosteroid, and corticosteroids of this type generally suppress inflammation on the ocular surface. That gives a plausible, general link to inflammatory conjunctivitis.
The record does not list the drug’s original approved indications, so the relationship between the original and predicted indications cannot be checked. No trial or paper evaluates prednisolone acetate in this condition. The high score therefore should not be read as clinical support.
Among the other candidates in this prediction set, vernal conjunctivitis (rank 9, score 99.58%) has the most supporting material. It has one disease-matched trial and a larger body of literature, including an experimental allergic conjunctivitis study comparing prednisolone acetate 1% with cyclosporine and epinastine. That evidence is still indirect and is classed L4. It is worth considering first if this drug moves forward.
Clinical Trial Evidence
Currently no related clinical trials registered. No SANCTR or PACTR entries were found either.
Literature Evidence
Currently no related literature available.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| J/15.2/73 | Pred-mild 5ml | Drops | Not stated in the registration record |
Essential Medicines List (EML) status for this product is not recorded in the available data.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high (99.74%), but there are no trials, no literature and no verifiable mechanism for this indication (evidence level L5). Safety data are also missing from the record, so the prediction cannot yet move to safety screening.
To proceed, the following is needed:
- The SAHPRA package insert (warnings, contraindications, approved indication), which is a blocking gap
- Mechanism of action data, for example from DrugBank
- Clarification of the etiology, since steroids may be unsuitable where infection is involved (for example parasitic or infectious causes)
- Assessment of intraocular pressure risk, which recurs across the topical steroid literature retrieved for other conjunctival indications
- Consideration of vernal conjunctivitis as the better-supported candidate, with direct prednisolone acetate efficacy data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.